In the past 6 years, widespread use of targeted therapies directed at the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) signaling pathways [18], [19] has greatly changed the clinical management of metastatic RCC. This evidence concerns the gene VEGFA and renal cell carcinoma.